Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment
New data from the PSMAddition study indicate that Pluvicto combined with standard of care, consisting of an androgen receptor pathway inhibitor plus androgen deprivation therapy, produced a 58% lower risk of prostate-specific antigen progression compared with standard of care alone. Patients rece...
Financing Boosts Vaccine Manufacturing Africa: New Facility to Enhance Local Production Capacity
In a major step forward for vaccine manufacturing Africa, Biovac has secured a financing package from the International Finance Corporation (IFC), the EIB Group, and the European Commission to build the continent’s first end-to-end multi-vaccine production facility.
Landmark Funding ...
Portugal’s MAP02 Medication Adherence Initiative: Enhancing Therapeutic Compliance through ...
MAP02 Medication Adherence stands out as Portugal’s latest digital solution for supporting elderly patients and those with psychomotor challenges who struggle with consistent medication use. Coordinated by the Polytechnic of Leiria through its ciTechCare research unit, the platform merges smart h...